Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS

Neuropharmacology

Volumn 124, Issue , 2017, Pages 157-169

  Pasquarelli, Noemi ^a,b   Engelskirchen, Michael ^a   Hanselmann, Johannes ^a   Endres, Sascha ^a   Porazik, Christoph ^a,b   Bayer, Hanna ^a   Buck, Eva ^a   Karsak, Meliha ^a,c   Weydt, Patrick ^a,d   Ferger, Boris ^b   Witting, Anke ^a  

^a UNIVERSITY OF ULM   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

2 Arachidonoylglycerol; Amyotrophic lateral sclerosis; Brain derived neurotrophic factor; Cannabinoid receptor 1; Endocannabinoid system; KML29; Monoacylglycerol lipase

Indexed keywords

ACYLGLYCEROL LIPASE; ACYLGLYCEROL LIPASE INHIBITOR; ARGINASE 1; BRAIN DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 6; KML 29; MESSENGER RNA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 1,1,1,3,3,3-HEXAFLUOROPROPAN-2-YL 4-(BIS(BENZO(D)(1,3)DIOXOL-5-YL)(HYDROXY)METHYL)PIPERIDINE-1-CARBOXYLATE; 1,3 BENZODIOXOLE DERIVATIVE; ACYLGLYCEROL; ARACHIDONIC ACID DERIVATIVE; ARG1 PROTEIN, MOUSE; ARGINASE; CYTOKINE; ENDOCANNABINOID; GLYCERYL 2-ARACHIDONATE; PIPERIDINE DERIVATIVE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; CONTROLLED STUDY; DISEASE COURSE; DRUG TARGETING; EMBRYO; FEMALE; IN VITRO STUDY; LIFESPAN; MALE; MICROGLIA; MOUSE; MOUSE MODEL; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD; TRANSGENIC MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; GLIA; METABOLISM; MOLECULARLY TARGETED THERAPY; PRIMARY CELL CULTURE; PROCEDURES;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ARACHIDONIC ACIDS; ARGINASE; BENZODIOXOLES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; FEMALE; GLYCERIDES; MALE; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; MONOACYLGLYCEROL LIPASES; NEUROGLIA; NEURONS; PIPERIDINES; PRIMARY CELL CULTURE; SPINAL CORD;

EID: 85017150045     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2017.03.037     Document Type: Article

References (66)

1. Acevedo-Arozena, A., Kalmar, B., Essa, S., Ricketts, T., Joyce, P., Kent, R., Rowe, C., Parker, A., Gray, A., Hafezparast, M., Thorpe, J.R., Greensmith, L., Fisher, E.M., A comprehensive assessment of the SOD1G93A low-copy transgenic mouse, which models human amyotrophic lateral sclerosis. Dis. Model Mech. 4 (2011), 686–700.
2. Apolloni, S., Amadio, S., Parisi, C., Matteucci, A., Potenza, R.L., Armida, M., Popoli, P., D'Ambrosi, N., Volonte, C., Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis. Dis. Model Mech. 7 (2014), 1101–1109.
3. Aso, E., Ozaita, A., Valdizan, E.M., Ledent, C., Pazos, A., Maldonado, R., Valverde, O., BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J. Neurochem. 105 (2008), 565–572.
4. Bilsland, L.G.G.L., The endocannabinoid system in amyotrophic lateral sclerosis. Curr. Pharm. Des. 14 (2008), 2306–2316.
5. Bilsland, L.G., Dick, J.R., Pryce, G., Petrosino, S., Di Marzo, V., Baker, D., Greensmith, L., Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 20 (2006), 1003–1005.
6. Biswas, S.K., Chittezhath, M., Shalova, I.N., Lim, J.Y., Macrophage polarization and plasticity in health and disease. Immunol. Res. 53 (2012), 11–24.
7. Blankman, J.L., Cravatt, B.F., Chemical probes of endocannabinoid metabolism. Pharmacol. Rev. 65 (2013), 849–871.
8. Blankman, J.L., Simon, G.M., Cravatt, B.F., A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14 (2007), 1347–1356.
9. Blázquez, C., Chiarlone, A., Sagredo, O., Aguado, T., Pazos, M.R., Resel, E., Palazuelos, J., Julien, B., Salazar, M., Borner, C., Benito, C., Carrasco, C., Diez-Zaera, M., Paoletti, P., Diaz-Hernandez, M., Ruiz, C., Sendtner, M., Lucas, J.J., de Yebenes, J.G., Marsicano, G., Monory, K., Lutz, B., Romero, J., Alberch, J., Gines, S., Kraus, J., Fernandez-Ruiz, J., Galve-Roperh, I., Guzmán, M., Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134 (2011), 119–136.
10. 1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway. Cell Death Differ. 22:10 (2015 Oct), 1618–1629, 10.1038/cdd.2015.11.
11. Butovsky, E., Juknat, A., Goncharov, I., Elbaz, J., Eilam, R., Zangen, A., Vogel, Z., In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol. J. Neurochem. 93 (2005), 802–811.
12. Butovsky, O., Jedrychowski, M.P., Cialic, R., Krasemann, S., Murugaiyan, G., Fanek, Z., Greco, D.J., Wu, P.M., Doykan, C.E., Kiner, O., Lawson, R.J., Frosch, M.P., Pochet, N., Fatimy, R.E., Krichevsky, A.M., Gygi, S.P., Lassmann, H., Berry, J., Cudkowicz, M.E., Weiner, H.L., Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann. Neurol. 77 (2015), 75–99.
13. Centonze, D., Finazzi-Agro, A., Bernardi, G., Maccarrone, M., The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol. Sci. 28 (2007), 180–187.
14. Chang, J.W., Niphakis, M.J., Lum, K.M., Cognetta, A.B. 3rd, Wang, C., Matthews, M.L., Niessen, S., Buczynski, M.W., Parsons, L.H., Cravatt, B.F., Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. Chem. Biol. 19 (2012), 579–588.
15. Chiurchiu, V., Leuti, A., Maccarrone, M., Cannabinoid signaling and neuroinflammatory diseases: a melting pot for the regulation of brain immune responses. J. Neuroimmune Pharmacol. 10 (2015), 268–280.
16. Cravatt, B.F., Giang, D.K., Mayfield, S.P., Boger, D.L., Lerner, R.A., Gilula, N.B., Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (1996), 83–87.
17. D'Souza, D.C., Pittman, B., Perry, E., Simen, A., Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacol. Berl. 202 (2009), 569–578.
18. Dal Canto, M.C., Gurney, M.E., Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am. J. Pathol. 145 (1994), 1271–1279.
19. Dal Canto, M.C., Gurney, M.E., Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res. 676 (1995), 25–40.
20. De March, Z., Zuccato, C., Giampa, C., Patassini, S., Bari, M., Gasperi, V., De Ceballos, M.L., Bernardi, G., Maccarrone, M., Cattaneo, E., Fusco, F.R., Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions. Neuroscience 152 (2008), 734–740.
21. DeJesus-Hernandez, M., Mackenzie, I.R., Boeve, B.F., Boxer, A.L., Baker, M., Rutherford, N.J., Nicholson, A.M., Finch, N.A., Flynn, H., Adamson, J., Kouri, N., Wojtas, A., Sengdy, P., Hsiung, G.Y., Karydas, A., Seeley, W.W., Josephs, K.A., Coppola, G., Geschwind, D.H., Wszolek, Z.K., Feldman, H., Knopman, D.S., Petersen, R.C., Miller, B.L., Dickson, D.W., Boylan, K.B., Graff-Radford, N.R., Rademakers, R., Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72 (2011), 245–256.
22. Di Marzo, V., Stella, N., Zimmer, A., Endocannabinoid signalling and the deteriorating brain. Nat. Rev. Neurosci. 16 (2015), 30–42.
23. Dinh, T.P., Freund, T.F., Piomelli, D., A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem. Phys. Lipids 121 (2002), 149–158.
24. Dócs, K., Hegyi, Z., Holló, K., Kis, G., Hegedűs, K., Antal, M., Selective axonal and glial distribution of monoacylglycerol lipase immunoreactivity in the superficial spinal dorsal horn of rodents. Brain Struct. Funct. 220:5 (2015 Sep), 2625–2637, 10.1007/s00429-014-0813-x.
25. Espejo-Porras, F., Piscitelli, F., Verde, R., Ramos, J.A., Di Marzo, V., de Lago, E., Fernandez-Ruiz, J., Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. J. Neuroimmune Pharmacol. 10 (2015), 233–244.
26. Fagan, S.G., Campbell, V.A., The influence of cannabinoids on generic traits of neurodegeneration. Br. J. Pharmacol. 171 (2014), 1347–1360.
27. Ferger, A.I., Campanelli, L., Reimer, V., Muth, K.N., Merdian, I., Ludolph, A.C., Witting, A., Effects of mitochondrial dysfunction on the immunological properties of microglia. J. Neuroinflammation, 7, 2010, 45.
28. Fernandez-Ruiz, J., Pazos, M.R., Garcia-Arencibia, M., Sagredo, O., Ramos, J.A., Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol. Cell Endocrinol. 286 (2008), S91–S96.
29. Franco, R., Fernaádez-Suárez, D., Alternatively activated microglia and macrophages in the central nervous system. Prog. Neurobiol. 131 (2015 Aug), 65–86, 10.1016/j.pneurobio.2015.05.003.
30. Gonsiorek, W., Lunn, C., Fan, X., Narula, S., Lundell, D., Hipkin, R.W., Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol. Pharmacol. 57 (2000), 1045–1050.
31. Graffmo, K.S., Forsberg, K., Bergh, J., Birve, A., Zetterstrom, P., Andersen, P.M., Marklund, S.L., Brannstrom, T., Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis. Hum. Mol. Genet. 22 (2013), 51–60.
32. Gurney, M.E., The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J. Neurol. Sci. 152:Suppl. 1 (1997), S67–S73.
33. Gurney, M.E., Pu, H., Chiu, A.Y., Dal Canto, M.C., Polchow, C.Y., Alexander, D.D., Caliendo, J., Hentati, A., Kwon, Y.W., Deng, H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264 (1994), 1772–1775.
34. Hellemans, J., Mortier, G., De Paepe, A., Speleman, F., Vandesompele, J., qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol., 8, 2007, R19.
35. Ignatowska-Jankowska, B.M., Ghosh, S., Crowe, M.S., Kinsey, S.G., Niphakis, M.J., Abdullah, R.A., Tao, Q., ST, O.N., Walentiny, D.M., Wiley, J.L., Cravatt, B.F., Lichtman, A.H., In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br. J. Pharmacol. 171 (2014), 1392–1407.
36. Kato, S., Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences. Acta Neuropathol. 115 (2008), 97–114.
37. Khaspekov, L.G., Brenz Verca, M.S., Frumkina, L.E., Hermann, H., Marsicano, G., Lutz, B., Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur. J. Neurosci. 19 (2004), 1691–1698.
38. Kim, K., Moore, D.H., Makriyannis, A., Abood, M.E., AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur. J. Pharmacol. 542 (2006), 100–105.
39. Lu, B., Nagappan, G., Guan, X., Nathan, P.J., Wren, P., BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat. Rev. Neurosci. 14 (2013), 401–416.
40. Ludolph, A.C., Jesse, S., Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials. Ther. Adv. Neurol. Disord. 2 (2009), 319–326.
41. Ludolph, A.C., Bendotti, C., Blaugrund, E., Chio, A., Greensmith, L., Loeffler, J.P., Mead, R., Niessen, H.G., Petri, S., Pradat, P.F., Robberecht, W., Ruegg, M., Schwalenstocker, B., Stiller, D., van den Berg, L., Vieira, F., von Horsten, S., Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph. Lateral Scler. 11 (2010), 38–45.
42. Maison, P., Walker, D.J., Walsh, F.S., Williams, G., Doherty, P., BDNF regulates neuronal sensitivity to endocannabinoids. Neurosci. Lett. 467 (2009), 90–94.
43. Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S.C., Cascio, M.G., Gutierrez, S.O., van der Stelt, M., Lopez-Rodriguez, M.L., Casanova, E., Schutz, G., Zieglgansberger, W., Di Marzo, V., Behl, C., Lutz, B., CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 (2003), 84–88.
44. Martinez, F.O., Helming, L., Gordon, S., Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27 (2009), 451–483.
45. McGoldrick, P., Joyce, P.I., Fisher, E.M., Greensmith, L., Rodent models of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1832 (2013), 1421–1436.
46. Mecha, M., Feliú, A., Carrillo-Salinas, F.J., Rueda-Zubiaurre, A., Ortega-Gutiérrez, S., de Sola, R.G., Guaza, C., Endocannabinoids drive the acquisition of an alternative phenotype in microglia. Brain, Behav. Immun. 49 (2015 Oct), 233–245, 10.1016/j.bbi.2015.06.002.
47. Mechoulam, R., Hanus, L.O., Pertwee, R., Howlett, A.C., Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat. Rev. Neurosci. 15 (2014), 757–764.
48. Moreno-Martet, M., Espejo-Porras, F., Fernandez-Ruiz, J., de Lago, E., Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex((R)) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci. Ther. 20 (2014), 809–815.
49. Naydenov, A.V., Sepers, M.D., Swinney, K., Raymond, L.A., Palmiter, R.D., Stella, N., Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice. Neurobiol. Dis. 71 (2014), 140–150.
50. Nomura, D.K., Morrison, B.E., Blankman, J.L., Long, J.Z., Kinsey, S.G., Marcondes, M.C., Ward, A.M., Hahn, Y.K., Lichtman, A.H., Conti, B., Cravatt, B.F., Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334 (2011), 809–813.
51. Pasquarelli, N., Porazik, C., Hanselmann, J., Weydt, P., Ferger, B., Witting, A., Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue. Neuropharmacology 91 (2015), 148–156.
52. Raman, C., McAllister, S.D., Rizvi, G., Patel, S.G., Moore, D.H., Abood, M.E., Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 5 (2004), 33–39.
53. Renton, A.E., Majounie, E., Waite, A., Simon-Sanchez, J., Rollinson, S., Gibbs, J.R., Schymick, J.C., Laaksovirta, H., van Swieten, J.C., Myllykangas, L., Kalimo, H., Paetau, A., Abramzon, Y., Remes, A.M., Kaganovich, A., Scholz, S.W., Duckworth, J., Ding, J., Harmer, D.W., Hernandez, D.G., Johnson, J.O., Mok, K., Ryten, M., Trabzuni, D., Guerreiro, R.J., Orrell, R.W., Neal, J., Murray, A., Pearson, J., Jansen, I.E., Sondervan, D., Seelaar, H., Blake, D., Young, K., Halliwell, N., Callister, J.B., Toulson, G., Richardson, A., Gerhard, A., Snowden, J., Mann, D., Neary, D., Nalls, M.A., Peuralinna, T., Jansson, L., Isoviita, V.M., Kaivorinne, A.L., Holtta-Vuori, M., Ikonen, E., Sulkava, R., Benatar, M., Wuu, J., Chio, A., Restagno, G., Borghero, G., Sabatelli, M., Consortium, I., Heckerman, D., Rogaeva, E., Zinman, L., Rothstein, J.D., Sendtner, M., Drepper, C., Eichler, E.E., Alkan, C., Abdullaev, Z., Pack, S.D., Dutra, A., Pak, E., Hardy, J., Singleton, A., Williams, N.M., Heutink, P., Pickering-Brown, S., Morris, H.R., Tienari, P.J., Traynor, B.J., A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72 (2011), 257–268.
54. Robberecht, W., Philips, T., The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 14 (2013), 248–264.
55. Rosen, D.R., Siddique, T., Patterson, D., Figlewicz, D.A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J.P., Deng, H.-X., Rahmani, Z., Krizus, A., McKenna-Yasek, D., Cayabyab, A., Gaston, S.M., Berger, R., Tanzi, R.E., Halperin, J.J., Herzfeldt, B., Van den Bergh, R., Hung, W.-Y., Bird, T., Deng, G., Mulder, D.W., Smyth, C., Laing, N.G., Soriano, E., Pericak-Vance, M.A., Haines, J., Rouleau, G.A., Gusella, J.S., Horvitz, H.R., Brown, R.H., Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993), 59–62.
56. Scotter, E.L., Abood, M.E., Glass, M., The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br. J. Pharmacol. 160 (2010), 480–498.
57. Shoemaker, J.L., Seely, K.A., Reed, R.L., Crow, J.P., Prather, P.L., The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J. Neurochem. 101 (2007), 87–98.
58. Tanimura, A., Uchigashima, M., Yamazaki, M., Uesaka, N., Mikuni, T., Abe, M., Hashimoto, K., Watanabe, M., Sakimura, K., Kano, M., Synapse type-independent degradation of the endocannabinoid 2-arachidonoylglycerol after retrograde synaptic suppression. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 12195–12200.
59. Turner, B.J., Talbot, K., Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog. Neurobiol. 85 (2008), 94–134.
60. Turner, M.R., Hardiman, O., Benatar, M., Brooks, B.R., Chio, A., de Carvalho, M., Ince, P.G., Lin, C., Miller, R.G., Mitsumoto, H., Nicholson, G., Ravits, J., Shaw, P.J., Swash, M., Talbot, K., Traynor, B.J., Van den Berg, L.H., Veldink, J.H., Vucic, S., Kiernan, M.C., Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 12 (2013), 310–322.
61. Wiesner, D., Merdian, I., Lewerenz, J., Ludolph, A.C., Dupuis, L., Witting, A., Fumaric acid esters stimulate astrocytic VEGF expression through HIF-1alpha and Nrf2. PLoS One, 8, 2013, e76670.
62. Witting, A., Weydt, P., Hong, S., Kliot, M., Moller, T., Stella, N., Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J. Neurochem. 89 (2004), 1555–1557.
63. Yiangou, Y., Facer, P., Durrenberger, P., Chessell, I.P., Naylor, A., Bountra, C., Banati, R.R., Anand, P., COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol., 6, 2006, 12.
64. Zhao, P., Ignacio, S., Beattie, E.C., Abood, M.E., Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. Eur. J. Neurosci. 27 (2008), 572–579.
65. Zhao, W., Beers, D.R., Appel, S.H., Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J. Neuroimmune Pharmacol. 8 (2013), 888–899.
66. Zuccato, C., Cattaneo, E., Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 5 (2009), 311–322.